MMP14 inhibition by NSC405020 (MMP14i, 2 mg/kg/day) led to a more robust tumor regression (Figure 8, D–G and Supplemental Figure 8, B and E) and decreased tumor vascularization (Figure 9, A–C), resulting in approximately 90% avascularity of tumor tissues but not adjacent regions (Figure 9D). Here, MMP14 is linked to neoplasm.